Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance
- 14 June 2012
- Vol. 98 (19), 1404-1406
- https://doi.org/10.1136/heartjnl-2012-302101
Abstract
The risk of stroke in AF is not homogeneous, and depends upon the presence or absence of several risk factors. These risk factors have been used to formulate stroke risk stratification schemes, so that the focus has been to identify ‘high-risk’ patients who could be targeted for this ‘inconvenient’ drug, warfarin.Keywords
This publication has 18 references indexed in Scilit:
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 2012
- The role of aspirin for stroke prevention in atrial fibrillationNature Reviews Cardiology, 2011
- Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of DabigatranThe New England Journal of Medicine, 2011
- Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patientsThrombosis and Haemostasis, 2011
- Validation of the CHADS2 clinical prediction rule to predict ischaemic strokeThrombosis and Haemostasis, 2011
- Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialThe Lancet, 2010
- Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic ReviewThe American Journal of Medicine, 2010
- New oral anticoagulant drugs in cardiovascular diseaseThrombosis and Haemostasis, 2010
- The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?Thrombosis and Haemostasis, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009